UTIAMC-GILT5BETA (NSE: GILT5BETA, BSE: 544103) is a Mumbai, Maharashtra-based company in the Mutual Fund Scheme industry. With a market capitalisation of ₹0 Cr, it ranks #6,142 by market cap among the 6,197 Indian listed companies on FinBizNet, and #110 of 115 in Mutual Fund Scheme. At ₹66.74 (as of 16 Nov 2026), the share price is 3.3% below its 52-week high of ₹69.00 and 6.1% above its 52-week low of ₹62.88. The share price is up 5.0% over one year and up 0.8% over three months.
| Current Price | ₹66.74 |
|---|---|
| Market Cap | ₹0 Cr |
| NSE Symbol | GILT5BETA |
| BSE Code | 544103 |
| Sector | Financials > Financial Services > Capital Markets |
| Sub-Industry | Mutual Fund Scheme |
| 52-Week Range | ₹62.88 – ₹69.00 |
| 1-Year Price Change | +5.0% |
| 3-Month Price Change | +0.8% |
| Beta (1Y) | 0.03 |
| Headquarters | Mumbai, Maharashtra |
Delivery averaged 93.8% of traded volume across 15 NSE sessions (23 Oct 2026 – 13 Nov 2026).
1. NA-NA 2. NA-NA 3. NA-NA 4. NA-NA
| Company | Market Cap | P/E | ROE | Latest Qtr Revenue | 1Y Change |
|---|---|---|---|---|---|
| EDELAMC - ENIFTY | ₹16 Cr | — | — | — | — |
| BANDHANAMC - SILVERBND | ₹10 Cr | — | — | — | — |
| GROWWAMC - GROWWCAPM | ₹8 Cr | — | — | — | — |
| KOTAKMAMC - CHEMICAL | ₹7 Cr | — | — | — | — |
| MOTILALAMC - MOMNC | ₹5 Cr | — | — | — | — |
| MOTILALAMC - MOPSE | ₹5 Cr | — | — | — | -1.7% |
| MOTILALAMC - MOTOUR | ₹5 Cr | — | — | — | -4.0% |
| UTIAMC-GILT5BETA | ₹0 Cr | — | — | — | +5.0% |
| 360ONEAMC - GOLD360 | ₹0 Cr | — | — | — | +56.7% |
Listed by market capitalisation. Ratios are shown for context only.
UTIAMC-GILT5BETA is trading at ₹66.74, with a market capitalisation of ₹0 Cr.
UTIAMC-GILT5BETA operates in the Financials > Financial Services > Capital Markets space (Mutual Fund Scheme).
UTIAMC-GILT5BETA is listed on the NSE under the symbol GILT5BETA and on the BSE under the scrip code 544103.
UTIAMC-GILT5BETA's share price is up 5.0% over one year and up 0.8% over three months. Its 52-week range is ₹62.88 to ₹69.00.
Data as of 16 Nov 2026. Descriptive market data only — not investment advice.